{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:39:47Z","timestamp":1790095187587,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The NASHmap model is a non-invasive tool using 14 variables (features) collected in standard clinical practice to classify patients as probable nonalcoholic steatohepatitis (NASH) or non-NASH, and here we have explored its performance and prediction accuracy. The National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) NAFLD Adult Database and the Optum Electronic Health Record (EHR) were used for patient data. Model performance metrics were calculated from correct and incorrect classifications for 281 NIDDK (biopsy-confirmed NASH and non-NASH, with and without stratification by type 2 diabetes status) and 1,016 Optum (biopsy-confirmed NASH) patients. NASHmap sensitivity in NIDDK is 81%, with a slightly higher sensitivity in T2DM patients (86%) than non-T2DM patients (77%). NIDDK patients misclassified by NASHmap had mean feature values distinct from correctly predicted patients, particularly for aspartate transaminase (AST; 75.88 U\/L true positive vs 34.94 U\/L false negative), and alanine transaminase (ALT; 104.09 U\/L vs 47.99 U\/L). Sensitivity was slightly lower in Optum at 72%. In an undiagnosed Optum cohort at risk for NASH (n\u2009=\u20092.9\u00a0M), NASHmap predicted 31% of patients as NASH. This predicted NASH group had AST and ALT mean levels above normal range of 0\u201335 U\/L, and 87% had HbA1C levels\u2009&gt;\u20095.7%. Overall, NASHmap demonstrates good sensitivity in predicting NASH status in both datasets, and NASH patients misclassified as non-NASH by NASHmap have clinical profiles closer to non-NASH patients.<\/jats:p>","DOI":"10.1038\/s41598-023-32551-2","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T11:02:50Z","timestamp":1680692570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settings"],"prefix":"10.1038","volume":"13","author":[{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Magdalena","family":"Balp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Reinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane A.","family":"Regnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorana","family":"Capkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos C.","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"32551_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"32551_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.14218\/JCTH.2014.00037","volume":"3","author":"QQ Zhang","year":"2015","unstructured":"Zhang, Q. Q. & Lu, L. G. Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy. J. Clin. Transl. Hepatol. 3, 78\u201384 (2015).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"32551_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-med-051215-031109","volume":"68","author":"A Suzuki","year":"2017","unstructured":"Suzuki, A. & Diehl, A. M. Nonalcoholic steatohepatitis. Annu. Rev. Med. 68, 85\u201398 (2017).","journal-title":"Annu. Rev. Med."},{"key":"32551_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/cells8080845","volume":"8","author":"HK Drescher","year":"2019","unstructured":"Drescher, H. K., Weiskirchen, S. & Weiskirchen, R. Current status in testing for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Cells 8, 845 (2019).","journal-title":"Cells"},{"key":"32551_CR5","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","volume":"17","author":"Y Huber","year":"2019","unstructured":"Huber, Y. et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin. Gastroenterol. Hepatol. 17, 2085\u20132092 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"32551_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/liv.14825","volume":"41","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg, J. M. et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int. 41, 1227\u20131243. https:\/\/doi.org\/10.1111\/liv.14825 (2021).","journal-title":"Liver Int."},{"key":"32551_CR7","doi-asserted-by":"publisher","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","volume":"20","author":"Y Takahashi","year":"2014","unstructured":"Takahashi, Y. & Fukusato, T. Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 15539\u201315548 (2014).","journal-title":"World J. Gastroenterol."},{"key":"32551_CR8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/jamia\/ocab003","volume":"28","author":"M Docherty","year":"2021","unstructured":"Docherty, M. et al. Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. JAMA 28, 1235\u20131241. https:\/\/doi.org\/10.1093\/jamia\/ocab003 (2021).","journal-title":"JAMA"},{"key":"32551_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"32551_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/apt.14976","volume":"48","author":"C Labenz","year":"2018","unstructured":"Labenz, C. et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment. Pharmacol. Ther. 48, 1109\u20131116 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"32551_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jhep.2004.07.010","volume":"41","author":"P Sorrentino","year":"2004","unstructured":"Sorrentino, P. et al. Silent non-alcoholic fatty liver disease\u2014A clinical-histological study. J. Hepatol. 41, 751\u2013757 (2004).","journal-title":"J. Hepatol."},{"key":"32551_CR12","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.3748\/wjg.15.1863","volume":"15","author":"HS Uslusoy","year":"2009","unstructured":"Uslusoy, H. S., Nak, S. G., Gulten, M. & Biyikli, Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J. Gastroenterol. 15, 1863\u20131868 (2009).","journal-title":"World J. Gastroenterol."},{"key":"32551_CR13","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1210\/jc.2015-1966","volume":"100","author":"P Portillo-Sanchez","year":"2015","unstructured":"Portillo-Sanchez, P. et al. High Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J. Clin. Endocrinol. Metab. 100, 2231\u20132238 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"32551_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12876-020-1165-z","volume":"20","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: A systematic review and meta-analysis. BMC Gastroenterol. 20, 10 (2020).","journal-title":"BMC Gastroenterol."},{"key":"32551_CR15","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner, D. E. et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. Open 2, e1912565 (2019).","journal-title":"JAMA Netw. Open"},{"key":"32551_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/hepr.13282","volume":"49","author":"K Tanaka","year":"2019","unstructured":"Tanaka, K. et al. Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. Hepatol. Res. 49, 296\u2013303 (2019).","journal-title":"Hepatol. Res."},{"key":"32551_CR17","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/hep4.1603","volume":"4","author":"GP Watt","year":"2020","unstructured":"Watt, G. P. et al. Elevated glycated hemoglobin is associated with liver fibrosis, as assessed by elastography, in a population-based study of Mexican Americans. Hepatol. Commun. 4, 1793\u20131801 (2020).","journal-title":"Hepatol. Commun."},{"key":"32551_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2337\/dc19-1113","volume":"43","author":"ZM Younossi","year":"2020","unstructured":"Younossi, Z. M. et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S. Diabetes Care 43, 283\u2013289 (2020).","journal-title":"Diabetes Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32551-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32551-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32551-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T11:04:27Z","timestamp":1680692667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32551-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32551"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32551-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"16 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JMS reports consulting fees from Boehringer Ingelheim, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, Novartis, Pfizer, Roche, and Siemens Healthineers. MMB, AT, GC, and JL are employees of Novartis Pharma AG. SAR and MCP were employees of Novartis Pharma AG at the time of study execution. BR, QY, and MD are employees of ZS Associates.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5573"}}